Thus, IFN-associated DNA methylation profiles may allow the prediction of disease activity and future patient stratification towards individualized treatment and care in patients with rare genetic forms of SLE/SLE-like disease and “classical” SLE. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.